BioCryst Pharmaceuticals | BCRX - 負債





負債 変化する 日付
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Chugai Pharma JPY 14.11B 1.93B 2022-12
Daiichi Sankyo JPY 201.14B 99.81B 2025-09
DBV Technologies USD 8.59M 295K 2025-09
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Gilead Sciences USD 24.94B 5M 2025-09
GlaxoSmithKline GBP 17.75B 396M 2025-09
Glaxosmithkline GBP 17.75B 396M 2025-09
Incyte USD 40.41M 855K 2025-12
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
Karyopharm Therapeutics USD 264.09M 39.31M 2024-09
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Novavax USD 233.31M 4.23M 2024-09
PTC Therapeutics USD 286.32M 306K 2025-09
Regeneron Pharmaceuticals USD 2.71B 400K 2025-09
Roche Holding CHF 33.03B 1.41B 2025-06
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Ultragenyx Pharmaceutical USD 33.83M 2.46M 2025-09
Vertex Pharmaceuticals USD 1.83B 307.4M 2025-09